1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 1,672 | 1,842 | 27.01. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| MOLECURE Aktie jetzt für 0€ handeln | |||||
| 28.03.25 | Strategic update on the progress and development of Molecure's key clinical projects in 2024 | 321 | GlobeNewswire (Europe) | Molecure achieved key milestones in the development of its innovative therapies in 2024 and plans to accelerate research and development in its most advanced clinical programs: OATD-01 and OATD-02.... ► Artikel lesen |
1 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CO.DON | 0,017 | -19,51 % | EQS-PVR: CO.DON AG: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung | EQS Stimmrechtsmitteilung: CO.DON AG
CO.DON AG: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung
07.01.2026 / 12:38 CET/CEST
Veröffentlichung... ► Artikel lesen | |
| SANGAMO THERAPEUTICS | 0,310 | -0,45 % | Sangamo Therapeutics, Inc.: Sangamo Therapeutics Initiates Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease | STAAR study demonstrated positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in the study, which U.S. Food and Drug Administration (FDA)... ► Artikel lesen | |
| IMMATICS | 8,430 | +1,63 % | Immatics Presents IMA203CD8 PRAME Cell Therapy Data from Ongoing Dose Escalation and Shows Promising Initial Anti-tumor Activity in PRAME-Positive Tumors at ESMO-IO 2025 Congress | IMA203CD8 is a second-generation PRAME cell therapy with enhanced pharmacology in ongoing Phase 1a dose escalationManageable tolerability across all dose levelsEncouraging early clinical anti-tumor... ► Artikel lesen | |
| ALDEYRA | 4,600 | -0,22 % | Aldeyra Therapeutics, Inc.: Aldeyra Therapeutics to Participate in the Jefferies Global Healthcare Conference in London | Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced... ► Artikel lesen | |
| MEDIFAST | 9,510 | -0,36 % | Medifast: OPTAVIA Premieres Second Docuseries Episode "Health by Design: Spain" Exploring Metabolic Health and Longevity | Thousands of Independent Coaches Gather Nationwide to Discuss Solutions to America's Metabolic Health Crisis Medifast (NYSE: MED), the health and wellness company known for its science-backed... ► Artikel lesen | |
| PHARMING | 1,800 | +0,61 % | Original-Research: Pharming Group NV (von First Berlin Equity Research GmbH): Buy | Original-Research: Pharming Group NV - from First Berlin Equity Research GmbH
21.01.2026 / 16:13 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The issuer... ► Artikel lesen | |
| COHERUS ONCOLOGY | 2,050 | -1,58 % | Coherus Oncology, Inc. - 8-K, Current Report | ||
| ORUKA THERAPEUTICS | 29,600 | +2,07 % | Oruka Therapeutics, Inc.: Oruka Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update | ORKA-001 Phase 1 results presented at EADV show potential for once-per-year dosing, higher efficacy and off-treatment remission Over $500M cash and equivalents provides runway over one year past three... ► Artikel lesen | |
| INNOVIVA | 16,700 | +1,83 % | FDA Approves Innoviva's NUZOLVENCE, First-in-Class Oral Treatment For Gonorrhea | ||
| ARMATA PHARMACEUTICALS | 5,400 | -0,92 % | Armata Pharmaceuticals, Inc. - 8-K, Current Report | ||
| DBV TECHNOLOGIES | 3,955 | -0,63 % | DBV Technologies S.A.: DBV Technologies Announces €166.7 Million in Gross Proceeds Following the Full Exercise of the ABSA Warrants and BS Warrants Issued on its March 2025 Financing | Châtillon, France, January 16, 2026
DBV Technologies Announces €166.7 Million in Gross Proceeds Following the Full Exercise of the ABSA Warrants and BS Warrants Issued on its March 2025 Financing... ► Artikel lesen | |
| BRAINSTORM CELL THERAPEUTICS | 0,673 | -100,00 % | BrainStorm Cell Therapeutics Inc.: BrainStorm Cell Therapeutics Announces Third Quarter 2025 Financial Results and Provides Corporate Update | NEW YORK, Nov. 14, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative... ► Artikel lesen | |
| SYNDAX PHARMACEUTICALS | 17,600 | -0,56 % | Syndax Pharmaceuticals, Inc.: Syndax Reports Third Quarter 2025 Financial Results and Provides Business Update | - $45.9 million in total revenue, representing 21% growth over 2Q25 - - $32.0 million Revuforj® (revumenib) net revenue; total Revuforj prescriptions in 3Q25 increased 25% over 2Q25, highlighting... ► Artikel lesen | |
| SIGA TECHNOLOGIES | 6,820 | +0,44 % | SIGA Technologies - Fundamentals intact amid several moving parts | Q325 was a quieter quarter for SIGA following strong Q2 sales, although this was not unexpected given its contract-driven model and inherent revenue lumpiness. No product sales were recorded, with total... ► Artikel lesen | |
| LIQUIDIA | 35,900 | +1,64 % | Liquidia Technologies, Inc.: Liquidia to Present Clinical Data Across Its Portfolio at the Pulmonary Vascular Research Institute 2026 Annual Congress |
MOLECURE SA gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 1,682 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MOLECURE SA finden Sie auf Wallstreet Online.